Firefly Neuroscience (AIFF) EBITDA Margin (2010 - 2026)
Firefly Neuroscience (AIFF) posted EBITDA Margin of 384.05% for Q2 2026, up 7.33% on a QoQ basis from 414.43% in Q1 2026, and up 16244.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Firefly Neuroscience (AIFF) EBITDA Margin (2010 - 2026) Analysis & Trends
Firefly Neuroscience has reported EBITDA Margin for 16 years, with the latest figure at 384.05% in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 16244.0% year-over-year to 384.05% in Q2 2026; TTM through Jun 2026 was 508.12%, a 251503.0% increase from a year earlier, with the FY2025 full-year figure at 775.48%, up 853378.0% from the prior year.
- EBITDA Margin was 384.05% for Q2 2026 at Firefly Neuroscience, up from 414.43% in the prior quarter.
- The five-year high for EBITDA Margin was 24.36% in Q2 2023, with the low at 12032.73% in Q3 2024.
- Average EBITDA Margin over 5 years is 2972.02%, with a median of 546.49% recorded in 2025.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin plunged 1070617 bps in 2024, then surged 1134819 bps in 2025.
- Over 5 years, EBITDA Margin stood at 51.38% in 2022, then slumped by 15951 bps to 8247.37% in 2023, then tumbled by 46 bps to 12032.73% in 2024, then surged by 95 bps to 607.04% in 2025, then soared by 37 bps to 384.05% in 2026.
- The last three EBITDA Margin figures came in at 384.05% (Q2 2026), 414.43% (Q1 2026), and 607.04% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 31.10 Bn | 29.22 Bn | 2.18 Bn | 13.96% |
| 2 | Lantheus Holdings | 6.59 Bn | 6.00 Bn | 241.86 Mn | 25.82% |
| 3 | Heartflow | 4.24 Bn | 3.87 Bn | 53.19 Mn | -27.93% |
| 4 | Neogen | 2.58 Bn | 2.39 Bn | 107.80 Mn | 1.38% |
| 5 | Butterfly Network | 1.75 Bn | 1.62 Bn | 23.29 Mn | -41.90% |
| 6 | QuidelOrtho | 954.15 Mn | 830.75 Mn | - | - |
| 7 | Ceribell | 944.88 Mn | 815.62 Mn | 25.94 Mn | -71.11% |
| 8 | Anbio Biotechnology | 941.05 Mn | 929.15 Mn | - | - |
| 9 | Varex Imaging | 780.16 Mn | 694.86 Mn | 76.70 Mn | 10.83% |
| 10 | Firefly Neuroscience | 23.25 Mn | 14.03 Mn | 253,000.00 | -384.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -384.05% |
| Mar 31, 2026 | -414.43% |
| Dec 31, 2025 | -607.04% |
| Sep 30, 2025 | -684.54% |
| Jun 30, 2025 | -546.49% |
| Mar 31, 2025 | -4,802.33% |
| Sep 30, 2024 | -12,032.73% |
| Jun 30, 2024 | -10,681.82% |
| Mar 31, 2024 | -9,091.67% |
| Dec 31, 2023 | -8,247.37% |
| Sep 30, 2023 | -2,813.04% |
| Jun 30, 2023 | 24.36% |
| Mar 31, 2023 | -44.20% |
| Dec 31, 2022 | -51.38% |
| Sep 30, 2022 | -49.00% |
| Jun 30, 2022 | -42.64% |
| Mar 31, 2022 | -55.99% |
| Dec 31, 2021 | 6.86% |
| Sep 30, 2021 | -1.96% |
| Jun 30, 2021 | 1.14% |